SERODUS ASA appoints scientific advisors for development program in Acute Myocardial Infarction (SER130)

Oslo, Norway, 17 December 2015: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the formation of a new Scientific Advisory Board for the development program in Acute Myocardial Infarction (SER130).

“As we have stated before we are very pleased that Serodus has attracted such a high quality Scientific Advisors. We are confident that the guidance will prove invaluable as the Company advances its development of SER130, a novel treatment for Acute Myocardial Infarction”. Says Eva Steiness, CEO in Serodus.

The appointed scientific advisors for the development program are:

 

Prof. Dan Atar, MD, Oslo University Hospital, Oslo, Norway

Dr. Atar, is Head of Research at Oslo University Hospital Ulleval, Dept. of Mecidine, Oslo, Norway, and holds a full Professorship in Cardiology at the University of Oslo, Norway, along with a Visiting Associate Professorship at the Johns Hopkins Unversity, Baltimore, Maryland, USA. His research focuses on myocardial biomarkers, myocardial function, heart failure and cardiovascular pharmacology.

 

Dr. A. Michael Lincoff, MD, Director, Center of Clinical Research and Vice Chairman for Clinical Research of the Lerner Research Institute, Cleveland, USA

Dr. Lincoff’s clinical research activities focus on development of therapies to reduce acute and long-term complications of percutaneous coronary revascularization procedures, to optimize therapy for acute coronary ischemic syndromes, or reduce progression or complications of atherosclerosis. He also oversees clinical research activities throughout the Cleveland Clinic as Director of the Center for Clinical Research and Vice Chairman for Clinical Research of the Lerner Research Institute.

Prof. Hans Erik Bøtker  Ph.D., MD., Aarhus University Hospital, Department of cardiology, Aarhus, Denmark

Dr. Bøtker is Professor of Cardiovascular Medicine and Interventional Cardiology and co-director of Department of Cardiology, Aarhus University Hospital Skejby, Denmark. He is past president of the Danish Society of Cardiology, advisor for  the European Board for Accreditation in Cardiology (EBAC) and member of the Working Group of Coronary Pathology and Microcirculation in the European Society of Cardiology.

For additional information of a more detail biography of the scientific advisors, please visit www.serodus.com or contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

 

Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.com.